Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of CYP-002 in Adults with Critical Limb Ischaemia Unsuitable for Revascularisation
2019-001361-33Phase 2Unknown
- Sponsor
- Cynata Therapeutics
- Start
- Dec 2019
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic limb-threatening ischemia (CLTI) comparing CYP-002 with Placebo (2 arms). Primary endpoint: Improvement in Rutherford Classification at 12 months. Status: unknown.
02
Drugs
CYP-002
03
Conditions
chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on 2019-001361-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001361-33.